About the Authors

Kuo-Hsiung Yang

kuohyang@email.unc.edu

Affiliation Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, United States of America

Craig Hendrix

Affiliation Departments of Medicine and Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America

Namandje Bumpus

Affiliation Departments of Medicine and Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America

Julie Elliott

Affiliation Center for HIV Prevention Research, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America

Karen Tanner

Affiliation Department of Biostatistics, UCLA School of Public Health, Los Angeles, California, United States of America

Christine Mauck

Affiliation CONRAD, Arlington, Virginia, United States of America

Ross Cranston

Affiliation Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

Ian McGowan

Affiliation Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

Nicola Richardson-Harman

Affiliation Alpha StatConsult LLC, Damascus, Maryland, United States of America

Peter A. Anton

Affiliation Center for HIV Prevention Research, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America

Angela D. M. Kashuba

Affiliation Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, United States of America

Competing Interests

The study was funded by a U19 grant under the Integrated Preclinical-Clinical Program for HIV Topical Microbicides (IPCP-HTM), Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) (AI060614) and the NIAID's Microbicide Trials Network (5UM1AI068633). Additional support was provided by Gilead Sciences Inc.; the University of California, Los Angeles Center for AIDS Research (5P30 AI28697) Cores of Mucosal Immunology, Flow Cytometry and Biostatistics; the University of North Carolina-Chapel Hill Center for AIDS Research, Clinical Pharmacology/Analytical Chemistry Core (P30 AI50410); the Johns Hopkins Clinical Pharmacology Analytical Laboratory and CONRAD. The RMP-02/MTN-006 study was registered at www.ClinicalTrials.gov (NCT00984971) and the protocol can be found at http://www.mtnstopshiv.org. This analysis was supported by a contract with Advanced BioScience Laboratories, Inc., Rockville, MD, and its subcontractor, Alpha StatConsult LLC, through a NIH/NIAID/DAIDS contract: "Comprehensive Resources for HIV Microbicides and Biomedical Prevention" (#HHSN272201000001C). This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Wrote the paper: KY CH RC IM PA AK. Conceived and designed the experiments: PA. Performed the experiments: CH NB JE CM RC IM PA. Analyzed the data: KY KT NR AK. Contributed reagents/materials/analysis tools: CH.